"Engineering Biology to Address Global Problems: Synthetic Biology Markets, Needs, and Applications"
Nancy J. Kelley, David J. Whelan, Ellyn Kerr, Aidan Apel,
Robyn Beliveau, and Rachael Scanlon
Nancy J. Kelley & Associates, New York, NY
This Industry Report includes key findings and excerpts from the report "Synberc Sustainability Initiative: Initial Findings & Recommendations", prepared by Nancy J. Kelley & Associates, February 2014, co-funded by the Alfred P. Sloan Foundation and Synberc. The full report is available at http://bit.ly/NJKAsynbio. The information and views contained in this document are those of the authors. They do not necessarily represent the views of Industrial Biotechnology, Mary Ann Liebert, Inc., publishers, or their affiliates. Furthermore, none of the above organizations or companies, nor any persons acting on their behalf, is responsible for the use that might be made of the information contained in this publication.
INDUSTRIAL BIOTECHNOLOGY JUNE 2014
DOI : 10.1089/ind.2014.1515
Diversity in Food Systems: The Case of Stockfree Organic
`
For more information, Please see websites below:
`
Organic Edible Schoolyards & Gardening with Children
http://scribd.com/doc/239851214
`
Double Food Production from your School Garden with Organic Tech
http://scribd.com/doc/239851079
`
Free School Gardening Art Posters
http://scribd.com/doc/239851159`
`
Companion Planting Increases Food Production from School Gardens
http://scribd.com/doc/239851159
`
Healthy Foods Dramatically Improves Student Academic Success
http://scribd.com/doc/239851348
`
City Chickens for your Organic School Garden
http://scribd.com/doc/239850440
`
Simple Square Foot Gardening for Schools - Teacher Guide
http://scribd.com/doc/239851110
Nowhere to Hide - Persistent Toxic Chemicals in the Food Supply v2zq
Â
Nowhere to Hide - Persistent Toxic Chemicals in the Food Supply - Resources for Healthy Children www.scribd.com/doc/254613619 - For more information, Please see Organic Edible Schoolyards & Gardening with Children www.scribd.com/doc/254613963 - Gardening with Volcanic Rock Dust www.scribd.com/doc/254613846 - Double Food Production from your School Garden with Organic Tech www.scribd.com/doc/254613765 - Free School Gardening Art Posters www.scribd.com/doc/254613694 - Increase Food Production with Companion Planting in your School Garden www.scribd.com/doc/254609890 - Healthy Foods Dramatically Improves Student Academic Success www.scribd.com/doc/254613619 - City Chickens for your Organic School Garden www.scribd.com/doc/254613553 - Huerto EcolĂłgico, TecnologĂas Sostenibles, Agricultura Organica www.scribd.com/doc/254613494 - Simple Square Foot Gardening for Schools - Teacher Guide www.scribd.com/doc/254613410 - Free Organic Gardening Publications www.scribd.com/doc/254609890 ~ pesticideresearch.com
1) Biotechnology is seen as the key solution to meeting the world's increasing food production needs over the next 40 years as the global population grows.
2) Brazil has made significant investments and progress in agricultural biotechnology, becoming an important global producer of food through the application of biotechnology.
3) Successful biotechnology programs require strong connections between private industry, universities, and the government to support research and commercialization efforts. Brazil's biotechnology sector has improved in this regard but still faces challenges around linking research to market opportunities.
The annual report of the Carl R. Woese Institute for Genomic Biology (IGB) summarizes the events of 2014. The report includes stories about IGB research accomplishments, partnerships, education initiatives, and community outreach. It also intersperses stories about notable world events to highlight connections between ongoing IGB work and global issues. The report demonstrates how the IGB brings together diverse expertise and collaborations to conduct transdisciplinary research aimed at addressing societal challenges.
Biotechnology and Medicine: Global Perspective
Gundu H R Rao, PhD
Emeritus Professor, Laboratory Medicine and Pathology, Anesthesiology, Lillehei Heart Institute, and Biomedical Engineering Institute, University of Minnesota, Minneapolis, Minnesota, USA 55455.
Gundurao9@gmail.com
There are more than 3000 biotech companies in the world. However, reliable sources indicate that only about 100 out of these 3000 companies, are offering commercial products. Majority of them depend on public or private funding for sustaining their operations. Of the 100 top biotech companies listed in Wikipedia, 70% of them are US companies. Only one from India and one from China are listed in this list of top 100 companies. The revenue generated ranges from a high of 15,000 million dollars to less than a few million dollars. Advance in biotechnology and biomedicine has contributed significantly, to the increased revenues in animal and agricultural products worldwide. Similarly, there is significant contribution in tissue engineering, drug discovery and development, development of biomarker assays for diagnostics, management of therapies, cellular and molecular therapies. China, one of the fastest developing economies, has initiated exchange program with 152 countries and signed memorandum of understanding with 96 countries, to become one of the major players in this field. One of the earliest and most significant biotechnology revolutions is the development of dairy industry in India. In the area of agriculture, India is the worldâs largest producer of sugar and sugarcane (285 million tones). India is the second largest producer of Potatoes in the world, after China. In the area of biomedicine, India produces 60% of the global health vaccines (USD 665Million) using the World Health Organization protocols. The growth of Biotechnology and biomedicine in India is sporadic. Department of Biotechnology, Government of India, feels that it is time now, to develop a well thought-out, robust, state-of-the-art biotechnology and biomedicine program in India. In this overview, I will share my concept of how these technologies should be developed in India, to meet the needs of the country as well as to be globally competitive.
It gives me great pleasure to share some of my thoughts with you all, on these two very important topics: biotechnology and biomedicine. Biotechnology as we know today contributes significantly, to the growth and progress of research, in all of the areas selected for discussion, under various âsub-themesâ for this international conference. The priority areas include, basic biology, biomedicine, bio-agriculture, bioenvironmental technology, biodiversity and bio-safety. Government of India has established a biotech park in Lucknow (UP), which houses 16 entrepreneurs, a Genome valley in Hyderabad, which is well supported by the State Government. Government of India also has approved the establishment of biotech parks in the States of Karn
This document is a newsletter from the Carl R. Woese Institute for Genomic Biology (IGB) at the University of Illinois at Urbana-Champaign. It discusses how the IGB is working to advance genomic research through new computational tools and large collaborations funded by NIH grants. It also highlights how new genomic data and analysis has helped rewrite understandings of bird and plant phylogenies as well as human migration to North America. The IGB brings researchers together in interdisciplinary themes to tackle fundamental problems in science. The newsletter provides updates on various IGB researchers' work involving crop physiology, cancer mutations, genome editing, antibiotic production, and more.
The document discusses innovation in cancer treatment in California. It notes that California companies have hundreds of oncology products in development that could lead to new lifesaving therapies. Continued investment is critical to ongoing research and development of new treatments. The pace of innovation has quickened in recent years, with 29 new cancer treatments approved nationally since 2008 alone.
The National Microbiome Initiative (NMI) was created in 2016 through the White House Office of Science and Technology Policy and various federal agencies and private investors to further research on microbiomes. The NMI has three main goals: 1) supporting research to answer fundamental questions about microbiomes in diverse ecosystems, 2) developing technologies to generate insights and enhance data sharing, and 3) expanding the microbiome workforce. Several federal agencies are involved in funding, including NIH, NASA, DOE, and NSF. The initiative aims to advance understanding of microbiome functions, composition, dynamics, and relationships through large-scale collaborative research efforts.
Diversity in Food Systems: The Case of Stockfree Organic
`
For more information, Please see websites below:
`
Organic Edible Schoolyards & Gardening with Children
http://scribd.com/doc/239851214
`
Double Food Production from your School Garden with Organic Tech
http://scribd.com/doc/239851079
`
Free School Gardening Art Posters
http://scribd.com/doc/239851159`
`
Companion Planting Increases Food Production from School Gardens
http://scribd.com/doc/239851159
`
Healthy Foods Dramatically Improves Student Academic Success
http://scribd.com/doc/239851348
`
City Chickens for your Organic School Garden
http://scribd.com/doc/239850440
`
Simple Square Foot Gardening for Schools - Teacher Guide
http://scribd.com/doc/239851110
Nowhere to Hide - Persistent Toxic Chemicals in the Food Supply v2zq
Â
Nowhere to Hide - Persistent Toxic Chemicals in the Food Supply - Resources for Healthy Children www.scribd.com/doc/254613619 - For more information, Please see Organic Edible Schoolyards & Gardening with Children www.scribd.com/doc/254613963 - Gardening with Volcanic Rock Dust www.scribd.com/doc/254613846 - Double Food Production from your School Garden with Organic Tech www.scribd.com/doc/254613765 - Free School Gardening Art Posters www.scribd.com/doc/254613694 - Increase Food Production with Companion Planting in your School Garden www.scribd.com/doc/254609890 - Healthy Foods Dramatically Improves Student Academic Success www.scribd.com/doc/254613619 - City Chickens for your Organic School Garden www.scribd.com/doc/254613553 - Huerto EcolĂłgico, TecnologĂas Sostenibles, Agricultura Organica www.scribd.com/doc/254613494 - Simple Square Foot Gardening for Schools - Teacher Guide www.scribd.com/doc/254613410 - Free Organic Gardening Publications www.scribd.com/doc/254609890 ~ pesticideresearch.com
1) Biotechnology is seen as the key solution to meeting the world's increasing food production needs over the next 40 years as the global population grows.
2) Brazil has made significant investments and progress in agricultural biotechnology, becoming an important global producer of food through the application of biotechnology.
3) Successful biotechnology programs require strong connections between private industry, universities, and the government to support research and commercialization efforts. Brazil's biotechnology sector has improved in this regard but still faces challenges around linking research to market opportunities.
The annual report of the Carl R. Woese Institute for Genomic Biology (IGB) summarizes the events of 2014. The report includes stories about IGB research accomplishments, partnerships, education initiatives, and community outreach. It also intersperses stories about notable world events to highlight connections between ongoing IGB work and global issues. The report demonstrates how the IGB brings together diverse expertise and collaborations to conduct transdisciplinary research aimed at addressing societal challenges.
Biotechnology and Medicine: Global Perspective
Gundu H R Rao, PhD
Emeritus Professor, Laboratory Medicine and Pathology, Anesthesiology, Lillehei Heart Institute, and Biomedical Engineering Institute, University of Minnesota, Minneapolis, Minnesota, USA 55455.
Gundurao9@gmail.com
There are more than 3000 biotech companies in the world. However, reliable sources indicate that only about 100 out of these 3000 companies, are offering commercial products. Majority of them depend on public or private funding for sustaining their operations. Of the 100 top biotech companies listed in Wikipedia, 70% of them are US companies. Only one from India and one from China are listed in this list of top 100 companies. The revenue generated ranges from a high of 15,000 million dollars to less than a few million dollars. Advance in biotechnology and biomedicine has contributed significantly, to the increased revenues in animal and agricultural products worldwide. Similarly, there is significant contribution in tissue engineering, drug discovery and development, development of biomarker assays for diagnostics, management of therapies, cellular and molecular therapies. China, one of the fastest developing economies, has initiated exchange program with 152 countries and signed memorandum of understanding with 96 countries, to become one of the major players in this field. One of the earliest and most significant biotechnology revolutions is the development of dairy industry in India. In the area of agriculture, India is the worldâs largest producer of sugar and sugarcane (285 million tones). India is the second largest producer of Potatoes in the world, after China. In the area of biomedicine, India produces 60% of the global health vaccines (USD 665Million) using the World Health Organization protocols. The growth of Biotechnology and biomedicine in India is sporadic. Department of Biotechnology, Government of India, feels that it is time now, to develop a well thought-out, robust, state-of-the-art biotechnology and biomedicine program in India. In this overview, I will share my concept of how these technologies should be developed in India, to meet the needs of the country as well as to be globally competitive.
It gives me great pleasure to share some of my thoughts with you all, on these two very important topics: biotechnology and biomedicine. Biotechnology as we know today contributes significantly, to the growth and progress of research, in all of the areas selected for discussion, under various âsub-themesâ for this international conference. The priority areas include, basic biology, biomedicine, bio-agriculture, bioenvironmental technology, biodiversity and bio-safety. Government of India has established a biotech park in Lucknow (UP), which houses 16 entrepreneurs, a Genome valley in Hyderabad, which is well supported by the State Government. Government of India also has approved the establishment of biotech parks in the States of Karn
This document is a newsletter from the Carl R. Woese Institute for Genomic Biology (IGB) at the University of Illinois at Urbana-Champaign. It discusses how the IGB is working to advance genomic research through new computational tools and large collaborations funded by NIH grants. It also highlights how new genomic data and analysis has helped rewrite understandings of bird and plant phylogenies as well as human migration to North America. The IGB brings researchers together in interdisciplinary themes to tackle fundamental problems in science. The newsletter provides updates on various IGB researchers' work involving crop physiology, cancer mutations, genome editing, antibiotic production, and more.
The document discusses innovation in cancer treatment in California. It notes that California companies have hundreds of oncology products in development that could lead to new lifesaving therapies. Continued investment is critical to ongoing research and development of new treatments. The pace of innovation has quickened in recent years, with 29 new cancer treatments approved nationally since 2008 alone.
The National Microbiome Initiative (NMI) was created in 2016 through the White House Office of Science and Technology Policy and various federal agencies and private investors to further research on microbiomes. The NMI has three main goals: 1) supporting research to answer fundamental questions about microbiomes in diverse ecosystems, 2) developing technologies to generate insights and enhance data sharing, and 3) expanding the microbiome workforce. Several federal agencies are involved in funding, including NIH, NASA, DOE, and NSF. The initiative aims to advance understanding of microbiome functions, composition, dynamics, and relationships through large-scale collaborative research efforts.
This document provides an overview of the winter 2016 edition of Biocom's LifeLines publication. It introduces the 10 winners of Biocom's inaugural Life Science Catalyst Awards, who are young entrepreneurs and leaders making significant contributions to the life sciences industry in California. Short profiles of two award winners are provided: Dena Marrinucci, founder of cancer diagnostics startup SalveoDx, and Mike Milligan, who leads the life sciences insurance practice at Barney & Barney. The rest of the document previews various articles in the publication on topics like public policy, partnering conferences, capital development, and Biocom's activities and membership in California.
Probiotics and prebiotics nrgastro.2014.66Elsa von Licy
Â
The document presents the conclusions of an expert panel convened by the International Scientific Association for Probiotics and Prebiotics (ISAPP) to discuss definitions and appropriate use of the term "probiotic".
The panel reaffirmed the FAO/WHO definition of probiotics as "live microorganisms that, when administered in adequate amounts, confer a health benefit on the host". The panel clarified inconsistencies between previous FAO/WHO reports and advanced the definition to account for scientific progress.
The panel concluded that certain health effects, such as supporting a healthy digestive tract and gut microbiota, can be reasonably expected from probiotic genera including Bifidobacterium and Lactobacillus. However
The Ohio Bioscience and Bioproducts Industry centers on research, development and marketing of pharmaceuticals, diagnostics, bioinformatics, bioproduct materials, manufacturing, medical devices, medical equipment, services based on biotechnology, computer systems and software for managing healthcare and other health-related products. Bioscience companies represent not only the next wave for the global economy but also opportunity for dramatic advances in the human experience.
With more than $2.5 billion in funding and 1,141 bioscience entities in operation throughout the state, Ohio is establishing an international leadership role in the cutting-edge bioscience industry.
Robert Mitchell (Duke University), "Ends and Means: Digital Labor in the Context of Health," Presentation for "The Internet as Playground and Factory," The New School, November 13, 2009
Numerous important Lifesciences locations, many of which are located on the West Coast, help make the United States life science sector the greatest in the world. In the life sciences, the West Coast is home to some of the most innovative work, alongside the East Coastâs more established hubs like Boston, New York, and New Jersey.
The document discusses the discovery of the antibiotic Teixobactin. It begins by providing context on the growing issue of antibiotic resistance and the challenges in discovering new antibiotics. It then describes the development of the Isolation Chip (I-chip) by researchers at Northeastern University, which allows for the isolated cultivation of previously uncultivable environmental bacteria. The I-chip led to the isolation and characterization of a new bacterium, Eleftheria terrae, which produces the potent antibiotic Teixobactin. Early studies found Teixobactin to have broad-spectrum bactericidal activity against many gram-positive pathogens, including MRSA, with high efficacy and low toxicity in mouse models. Teixobactin represents a promising new
The document summarizes California's strong biomedical industry in 2015. It notes that California leads the nation in biomedical research and development, supporting over 270,000 high-paying jobs. The state's world-class universities and research institutions attract billions in funding each year to advance scientific discovery and develop new medicines and technologies. California's biomedical sector had $101 billion in revenues in 2013 and continues to be an economic driver in the state.
Neuroscience is poised for increased deal activity after a period of setbacks. Advances in clinical trial design, imaging, and biomarkers are driving interest in neuroscience drugs. Venture funding and licensing deals in neurology and psychiatry totaled billions from 2005-2014, though M&A activity was lower. Recent large neuroscience acquisitions by companies like Celgene, Teva, and Biogen have sparked renewed enthusiasm. Experts predict precision medicine approaches will increase dealmaking as neurological diseases are further subtyped genetically.
Dr. Alan Bernstein, president of the Canadian Institutes of Health Research (CIHR), has set an ambitious goal to turn Canada's $20 billion annual healthcare spending into a research-driven enterprise to capture both health and economic benefits. Under Bernstein's leadership, the CIHR has increased funding for healthcare research significantly, focusing on areas like health services research and population health that have the potential to improve healthcare delivery and identify preventative strategies. The CIHR also aims to commercialize research discoveries in Canada in order to fund new research, reward scientists, and retain top talent in the country. Several examples are provided of research institutions and startups that have successfully commercialized healthcare technologies and therapies with support from the CIHR.
This document summarizes the BioVision 2013 conference held in Lyon, France. It discusses several topics related to biomedical research and innovation. Key points include the importance of supporting young researchers, the potential of gene research this century, positive indicators for the healthcare sector in France, and over 200 million euros currently spent on translational research. The conference featured discussions on synergizing research efforts, supporting startups, new medical treatments, and catalyzing innovation through cross-disciplinary approaches. Speakers represented industry, government, and academia and addressed issues like climate change, regulating drug development and access, and enabling new biomanufacturing technologies.
This document discusses biotechnology and its role in addressing the COVID-19 pandemic. It outlines the main branches of biotechnology including blue, green, bioinformatics, red, and white biotechnology. It also lists top biotech companies in India and specializations within biotechnology. The document explains opportunities for biotech companies to develop vaccines, drugs, and medical equipment for COVID-19. Governments are supporting biotech industry efforts to rapidly develop treatments and remedies for the pandemic.
America's Choice - Children's Health or Corporate Profit v2zq
Â
America's Choice - Children's Health or Corporate Profit - Resources for Healthy Children www.scribd.com/doc/254613619 - For more information, Please see Organic Edible Schoolyards & Gardening with Children www.scribd.com/doc/254613963 - Gardening with Volcanic Rock Dust www.scribd.com/doc/254613846 - Double Food Production from your School Garden with Organic Tech www.scribd.com/doc/254613765 - Free School Gardening Art Posters www.scribd.com/doc/254613694 - Increase Food Production with Companion Planting in your School Garden www.scribd.com/doc/254609890 - Healthy Foods Dramatically Improves Student Academic Success www.scribd.com/doc/254613619 - City Chickens for your Organic School Garden www.scribd.com/doc/254613553 - Huerto EcolĂłgico, TecnologĂas Sostenibles, Agricultura Organica www.scribd.com/doc/254613494 - Simple Square Foot Gardening for Schools - Teacher Guide www.scribd.com/doc/254613410 - Free Organic Gardening Publications www.scribd.com/doc/254609890 ~
PPT - General Essay Writing Tips And Essay Writing CeAngela Garcia
Â
This article discusses coerced false confessions resulting from police interrogations. It describes how interrogation techniques like isolation, threats, and promises can psychologically coerce innocent suspects into falsely confessing. The article notes that these techniques take advantage of people's natural desire to trust authorities and avoid punishment. It also explains that once people have confessed falsely, they may internalize their confession and come to believe their own false story. The article argues that reforms are needed to reduce the risk of coerced false confessions during police interrogations.
CONCEPT AND SCOPE OF BIOTECHNOLOGY BY AARIFAARIF MAQBOOL
Â
This document provides an overview of biotechnology, including its history, concept, and scope. It notes that biotechnology has been used for thousands of years in processes like brewing beer and making cheese, but emerged as a science around 100 years ago with pioneers like Pasteur. Modern biotechnology uses techniques such as recombinant DNA, PCR, and gene cloning and has applications in pharmaceuticals, agriculture, food production, waste treatment and more. It is a large, growing industry employing hundreds of thousands of people worldwide.
Designing of drug delivery system for biotechnology products considering stab...Smaranika Rahman
Â
This document discusses drug delivery systems for biotechnology products, focusing on stability aspects and monitoring methods to improve stability. It provides background on biotechnology and its history, then describes various routes for delivering biotech products, including orally, nasally, transdermally, parenterally, and rectally. For each route, it discusses technologies being investigated or developed to enhance stability and absorption of biotech drugs, such as using polymers, absorption enhancers, and targeted delivery methods. The goal is to develop delivery systems that can safely and reliably deliver biotech medications at therapeutic levels.
This document provides information about the 4th edition of the textbook "Biochemistry" by Donald Voet and Judith G. Voet. It lists the publisher, editors, production staff, and copyright information for the textbook. It also provides a brief preface written by the authors that introduces the intended audience for the textbook and discusses some of its themes and organization. The preface emphasizes that biochemistry is a growing field shaped by experimentation and the efforts of individual scientists, and that it illustrates the unity of life through evolution as well as the importance of control networks and medical applications.
Mandy Hagan - Advancing Technologies to Feed 9 BillionJohn Blue
Â
Advancing Technologies to Feed 9 Billion - Mandy Hagan, Vice President, State Affairs and Grassroots, Grocery Manufacturers Association, from the 2015 Animal Agriculture Alliance Stakeholders Summit, The Journey to Extraordinary, May 6 - 7, 2015, Kansas City, MO, USA.
More presentations at http://www.trufflemedia.com/agmedia/conference/2015-the-journey-to-extraordinary
Federal funding for biomedical research has declined significantly in recent years due to budget constraints. This threatens scientific progress and the development of new treatments. Industry and universities must explore new collaborations to supplement decreased government funding. Innovative public-private partnerships and new funding models are needed to sustain world-class biomedical research and innovation in the US.
Andreas Schleicher presents PISA 2022 Volume III - Creative Thinking - 18 Jun...EduSkills OECD
Â
Andreas Schleicher, Director of Education and Skills at the OECD presents at the launch of PISA 2022 Volume III - Creative Minds, Creative Schools on 18 June 2024.
More Related Content
Similar to Engineering Biology to Address Global Problems: Synthetic Biology Markets, Needs, and Applications
This document provides an overview of the winter 2016 edition of Biocom's LifeLines publication. It introduces the 10 winners of Biocom's inaugural Life Science Catalyst Awards, who are young entrepreneurs and leaders making significant contributions to the life sciences industry in California. Short profiles of two award winners are provided: Dena Marrinucci, founder of cancer diagnostics startup SalveoDx, and Mike Milligan, who leads the life sciences insurance practice at Barney & Barney. The rest of the document previews various articles in the publication on topics like public policy, partnering conferences, capital development, and Biocom's activities and membership in California.
Probiotics and prebiotics nrgastro.2014.66Elsa von Licy
Â
The document presents the conclusions of an expert panel convened by the International Scientific Association for Probiotics and Prebiotics (ISAPP) to discuss definitions and appropriate use of the term "probiotic".
The panel reaffirmed the FAO/WHO definition of probiotics as "live microorganisms that, when administered in adequate amounts, confer a health benefit on the host". The panel clarified inconsistencies between previous FAO/WHO reports and advanced the definition to account for scientific progress.
The panel concluded that certain health effects, such as supporting a healthy digestive tract and gut microbiota, can be reasonably expected from probiotic genera including Bifidobacterium and Lactobacillus. However
The Ohio Bioscience and Bioproducts Industry centers on research, development and marketing of pharmaceuticals, diagnostics, bioinformatics, bioproduct materials, manufacturing, medical devices, medical equipment, services based on biotechnology, computer systems and software for managing healthcare and other health-related products. Bioscience companies represent not only the next wave for the global economy but also opportunity for dramatic advances in the human experience.
With more than $2.5 billion in funding and 1,141 bioscience entities in operation throughout the state, Ohio is establishing an international leadership role in the cutting-edge bioscience industry.
Robert Mitchell (Duke University), "Ends and Means: Digital Labor in the Context of Health," Presentation for "The Internet as Playground and Factory," The New School, November 13, 2009
Numerous important Lifesciences locations, many of which are located on the West Coast, help make the United States life science sector the greatest in the world. In the life sciences, the West Coast is home to some of the most innovative work, alongside the East Coastâs more established hubs like Boston, New York, and New Jersey.
The document discusses the discovery of the antibiotic Teixobactin. It begins by providing context on the growing issue of antibiotic resistance and the challenges in discovering new antibiotics. It then describes the development of the Isolation Chip (I-chip) by researchers at Northeastern University, which allows for the isolated cultivation of previously uncultivable environmental bacteria. The I-chip led to the isolation and characterization of a new bacterium, Eleftheria terrae, which produces the potent antibiotic Teixobactin. Early studies found Teixobactin to have broad-spectrum bactericidal activity against many gram-positive pathogens, including MRSA, with high efficacy and low toxicity in mouse models. Teixobactin represents a promising new
The document summarizes California's strong biomedical industry in 2015. It notes that California leads the nation in biomedical research and development, supporting over 270,000 high-paying jobs. The state's world-class universities and research institutions attract billions in funding each year to advance scientific discovery and develop new medicines and technologies. California's biomedical sector had $101 billion in revenues in 2013 and continues to be an economic driver in the state.
Neuroscience is poised for increased deal activity after a period of setbacks. Advances in clinical trial design, imaging, and biomarkers are driving interest in neuroscience drugs. Venture funding and licensing deals in neurology and psychiatry totaled billions from 2005-2014, though M&A activity was lower. Recent large neuroscience acquisitions by companies like Celgene, Teva, and Biogen have sparked renewed enthusiasm. Experts predict precision medicine approaches will increase dealmaking as neurological diseases are further subtyped genetically.
Dr. Alan Bernstein, president of the Canadian Institutes of Health Research (CIHR), has set an ambitious goal to turn Canada's $20 billion annual healthcare spending into a research-driven enterprise to capture both health and economic benefits. Under Bernstein's leadership, the CIHR has increased funding for healthcare research significantly, focusing on areas like health services research and population health that have the potential to improve healthcare delivery and identify preventative strategies. The CIHR also aims to commercialize research discoveries in Canada in order to fund new research, reward scientists, and retain top talent in the country. Several examples are provided of research institutions and startups that have successfully commercialized healthcare technologies and therapies with support from the CIHR.
This document summarizes the BioVision 2013 conference held in Lyon, France. It discusses several topics related to biomedical research and innovation. Key points include the importance of supporting young researchers, the potential of gene research this century, positive indicators for the healthcare sector in France, and over 200 million euros currently spent on translational research. The conference featured discussions on synergizing research efforts, supporting startups, new medical treatments, and catalyzing innovation through cross-disciplinary approaches. Speakers represented industry, government, and academia and addressed issues like climate change, regulating drug development and access, and enabling new biomanufacturing technologies.
This document discusses biotechnology and its role in addressing the COVID-19 pandemic. It outlines the main branches of biotechnology including blue, green, bioinformatics, red, and white biotechnology. It also lists top biotech companies in India and specializations within biotechnology. The document explains opportunities for biotech companies to develop vaccines, drugs, and medical equipment for COVID-19. Governments are supporting biotech industry efforts to rapidly develop treatments and remedies for the pandemic.
America's Choice - Children's Health or Corporate Profit v2zq
Â
America's Choice - Children's Health or Corporate Profit - Resources for Healthy Children www.scribd.com/doc/254613619 - For more information, Please see Organic Edible Schoolyards & Gardening with Children www.scribd.com/doc/254613963 - Gardening with Volcanic Rock Dust www.scribd.com/doc/254613846 - Double Food Production from your School Garden with Organic Tech www.scribd.com/doc/254613765 - Free School Gardening Art Posters www.scribd.com/doc/254613694 - Increase Food Production with Companion Planting in your School Garden www.scribd.com/doc/254609890 - Healthy Foods Dramatically Improves Student Academic Success www.scribd.com/doc/254613619 - City Chickens for your Organic School Garden www.scribd.com/doc/254613553 - Huerto EcolĂłgico, TecnologĂas Sostenibles, Agricultura Organica www.scribd.com/doc/254613494 - Simple Square Foot Gardening for Schools - Teacher Guide www.scribd.com/doc/254613410 - Free Organic Gardening Publications www.scribd.com/doc/254609890 ~
PPT - General Essay Writing Tips And Essay Writing CeAngela Garcia
Â
This article discusses coerced false confessions resulting from police interrogations. It describes how interrogation techniques like isolation, threats, and promises can psychologically coerce innocent suspects into falsely confessing. The article notes that these techniques take advantage of people's natural desire to trust authorities and avoid punishment. It also explains that once people have confessed falsely, they may internalize their confession and come to believe their own false story. The article argues that reforms are needed to reduce the risk of coerced false confessions during police interrogations.
CONCEPT AND SCOPE OF BIOTECHNOLOGY BY AARIFAARIF MAQBOOL
Â
This document provides an overview of biotechnology, including its history, concept, and scope. It notes that biotechnology has been used for thousands of years in processes like brewing beer and making cheese, but emerged as a science around 100 years ago with pioneers like Pasteur. Modern biotechnology uses techniques such as recombinant DNA, PCR, and gene cloning and has applications in pharmaceuticals, agriculture, food production, waste treatment and more. It is a large, growing industry employing hundreds of thousands of people worldwide.
Designing of drug delivery system for biotechnology products considering stab...Smaranika Rahman
Â
This document discusses drug delivery systems for biotechnology products, focusing on stability aspects and monitoring methods to improve stability. It provides background on biotechnology and its history, then describes various routes for delivering biotech products, including orally, nasally, transdermally, parenterally, and rectally. For each route, it discusses technologies being investigated or developed to enhance stability and absorption of biotech drugs, such as using polymers, absorption enhancers, and targeted delivery methods. The goal is to develop delivery systems that can safely and reliably deliver biotech medications at therapeutic levels.
This document provides information about the 4th edition of the textbook "Biochemistry" by Donald Voet and Judith G. Voet. It lists the publisher, editors, production staff, and copyright information for the textbook. It also provides a brief preface written by the authors that introduces the intended audience for the textbook and discusses some of its themes and organization. The preface emphasizes that biochemistry is a growing field shaped by experimentation and the efforts of individual scientists, and that it illustrates the unity of life through evolution as well as the importance of control networks and medical applications.
Mandy Hagan - Advancing Technologies to Feed 9 BillionJohn Blue
Â
Advancing Technologies to Feed 9 Billion - Mandy Hagan, Vice President, State Affairs and Grassroots, Grocery Manufacturers Association, from the 2015 Animal Agriculture Alliance Stakeholders Summit, The Journey to Extraordinary, May 6 - 7, 2015, Kansas City, MO, USA.
More presentations at http://www.trufflemedia.com/agmedia/conference/2015-the-journey-to-extraordinary
Federal funding for biomedical research has declined significantly in recent years due to budget constraints. This threatens scientific progress and the development of new treatments. Industry and universities must explore new collaborations to supplement decreased government funding. Innovative public-private partnerships and new funding models are needed to sustain world-class biomedical research and innovation in the US.
Similar to Engineering Biology to Address Global Problems: Synthetic Biology Markets, Needs, and Applications (20)
Andreas Schleicher presents PISA 2022 Volume III - Creative Thinking - 18 Jun...EduSkills OECD
Â
Andreas Schleicher, Director of Education and Skills at the OECD presents at the launch of PISA 2022 Volume III - Creative Minds, Creative Schools on 18 June 2024.
Brand Guideline of Bashundhara A4 Paper - 2024khabri85
Â
It outlines the basic identity elements such as symbol, logotype, colors, and typefaces. It provides examples of applying the identity to materials like letterhead, business cards, reports, folders, and websites.
How to Setup Default Value for a Field in Odoo 17Celine George
Â
In Odoo, we can set a default value for a field during the creation of a record for a model. We have many methods in odoo for setting a default value to the field.
How to Download & Install Module From the Odoo App Store in Odoo 17Celine George
Â
Custom modules offer the flexibility to extend Odoo's capabilities, address unique requirements, and optimize workflows to align seamlessly with your organization's processes. By leveraging custom modules, businesses can unlock greater efficiency, productivity, and innovation, empowering them to stay competitive in today's dynamic market landscape. In this tutorial, we'll guide you step by step on how to easily download and install modules from the Odoo App Store.
THE SACRIFICE HOW PRO-PALESTINE PROTESTS STUDENTS ARE SACRIFICING TO CHANGE T...indexPub
Â
The recent surge in pro-Palestine student activism has prompted significant responses from universities, ranging from negotiations and divestment commitments to increased transparency about investments in companies supporting the war on Gaza. This activism has led to the cessation of student encampments but also highlighted the substantial sacrifices made by students, including academic disruptions and personal risks. The primary drivers of these protests are poor university administration, lack of transparency, and inadequate communication between officials and students. This study examines the profound emotional, psychological, and professional impacts on students engaged in pro-Palestine protests, focusing on Generation Z's (Gen-Z) activism dynamics. This paper explores the significant sacrifices made by these students and even the professors supporting the pro-Palestine movement, with a focus on recent global movements. Through an in-depth analysis of printed and electronic media, the study examines the impacts of these sacrifices on the academic and personal lives of those involved. The paper highlights examples from various universities, demonstrating student activism's long-term and short-term effects, including disciplinary actions, social backlash, and career implications. The researchers also explore the broader implications of student sacrifices. The findings reveal that these sacrifices are driven by a profound commitment to justice and human rights, and are influenced by the increasing availability of information, peer interactions, and personal convictions. The study also discusses the broader implications of this activism, comparing it to historical precedents and assessing its potential to influence policy and public opinion. The emotional and psychological toll on student activists is significant, but their sense of purpose and community support mitigates some of these challenges. However, the researchers call for acknowledging the broader Impact of these sacrifices on the future global movement of FreePalestine.
CapTechTalks Webinar Slides June 2024 Donovan Wright.pptxCapitolTechU
Â
Slides from a Capitol Technology University webinar held June 20, 2024. The webinar featured Dr. Donovan Wright, presenting on the Department of Defense Digital Transformation.
A Free 200-Page eBook ~ Brain and Mind Exercise.pptxOH TEIK BIN
Â
(A Free eBook comprising 3 Sets of Presentation of a selection of Puzzles, Brain Teasers and Thinking Problems to exercise both the mind and the Right and Left Brain. To help keep the mind and brain fit and healthy. Good for both the young and old alike.
Answers are given for all the puzzles and problems.)
With Metta,
Bro. Oh Teik Bin đđ€đ€đ„°
A Visual Guide to 1 Samuel | A Tale of Two HeartsSteve Thomason
Â
These slides walk through the story of 1 Samuel. Samuel is the last judge of Israel. The people reject God and want a king. Saul is anointed as the first king, but he is not a good king. David, the shepherd boy is anointed and Saul is envious of him. David shows honor while Saul continues to self destruct.
220711130083 SUBHASHREE RAKSHIT Internet resources for social science
Â
Engineering Biology to Address Global Problems: Synthetic Biology Markets, Needs, and Applications
1. Industry Reports
Engineering Biology to Address Global Problems:
Synthetic Biology Markets, Needs, and Applications
Nancy J. Kelley, David J. Whelan, Ellyn Kerr, Aidan Apel,
Robyn Beliveau, and Rachael Scanlon
Nancy J. Kelley & Associates, New York, NY
Introduction
S
ynthetic biologyâthe design and construction of new
biological parts, devices, and systems, and the redesign
of natural biological systems for useful purposesâ
opens the richness of biological diversity to solve
pressing, real-world problems for humanity and the planet:
precisely targeted, personalized medicines; energy-rich mole-
cules for sustainable fuels and industrial chemicals; remediation
of polluted environments; and food supplies to meet an explo-
sively growing global population.1
Still, we are far from capi-
talizing on synthetic biologyâs fullest potentialâa promise that
also poses great ethical questions and risks. This places a critical
onus on researchers, policymakers, regulatory bodies, industry,
and all citizen stakeholders to engage in an intelligent dialogue
about how to advance synthetic biology not only to sustain but
also to enhance life on Earth.
With an expected global market of $10.8 billion by 2016,
synthetic biology will play an important role in the bioeconomy
with powerful implications for future US competitiveness and
employment.2
The US currently leads the world in intellectual
conception, research, and commercial development in this
field.2,3
But in both industry and research in the US and
worldwide, synthetic biology is hampered by a lack of stan-
dardized fundamental tools, inadequate regulatory policy, a
need for both substantial public and private investment, and lack
of education of stakeholders about its risks and benefits.
This report reviews the development of synthetic biology
from a historical perspective, within a global landscape of reg-
ulatory frameworks, funding initiatives, and social and ethical
aspects. The full version of this report was prepared as part of a
1-year independent initiative funded by the Alfred P. Sloan
Foundation and Synberc.4
Much foundational research is yet
needed, as well as supportive policy and sufficient financial
investment, if the US is to maintain and grow its leadership
position in this field it has pioneered.
Synbio: The First 15 Years
While research in synbio and adjacent fields has been un-
derway for decades, the field emerged on its own around the turn
of the century with a few seminal events, including Blue Heronâs
(Bothell, WA) and GeneArtâs (Grand Island, NY) launch of the
gene-synthesis industry (1999), Jim Collinsâ Nature paper on
bacterial toggle switches (2000), the initial sequencing of the
human genome (2001), and the introduction of the BioBricks
concept by Tom Knight (2003). Since then, the pace of devel-
opment has rapidly accelerated, with a cascade of research,
funding, and corporate activity. This is obvious from the pub-
lishing volume over this period: in 2003, fewer than ten articles
in the scientific literature related to synthetic biology; by 2011,
that number had grown to approximately 350, including articles,
reviews, proceedings, etc. (Fig. 1).
The majority of these publications have stemmed from US
research, but the field is growing rapidly elsewhere. Recent UK
investments should lead to even greater outputs, and European
efforts are gaining momentum. China, which intends to become
a significant synbio player within 10 years, now contributes 10%
of all synthetic biology papers published.5,6
The timeline in
Figure 2 highlights developments in synbio over the past 15
years.
In 2002, the US Department of Energy (DOE) invested $12
million in Craig Venterâs research as part of its Genomes to Life
Program, followed by the Department of Defenseâs (DOD)
Defense Advanced Research Projects Agency (DARPA) in-
vestigation into the intersection of computing and biology. US
investment into synbio has totaled at least $500 million (by
NJK&A estimates, up to $1 billion), spanning multiple agencies
and supporting numerous research efforts and institutions.9
The
largest single investment to date has been National Science
Foundationâs (NSFâs) support of the Synthetic Biology Re-
search Engineering Center (Synberc, www.synberc.org), begun
in 2006 by a handful of researchers from University of
California, Berkeley, Harvard University, MIT, University of
California, San Francisco, and Stanford University, and now
EDITORâS NOTE: This Industry Report includes key findings
and excerpts from the report ââSynberc Sustainability
Initiative: Initial Findings & Recommendations,ââ prepared
by Nancy J. Kelley & Associates, February 2014, co-funded by
the Alfred P. Sloan Foundation and Synberc. The full report
is available at http://bit.ly/NJKAsynbio. The information and
views contained in this document are those of the authors.
They do not necessarily represent the views of Industrial
Biotechnology, Mary Ann Liebert, Inc., publishers, or their
affiliates. Furthermore, none of the above organizations or
companies, nor any persons acting on their behalf, is
responsible for the use that might be made of the
information contained in this publication.
140 INDUSTRIAL BIOTECHNOLOGY JUNE 2014 DOI: 10.1089/ind.2014.1515
2. comprised of a substantial community of researchers and in-
dustry partners nationwide.
Several institutional affiliates of Synberc have developed
their own synbio-related programs and centers over the past
decade, with other US schools following suit. Meanwhile, nu-
merous multinational corporationsâincluding Agilent Technolo-
gies (Santa Clara, CA), Life Technologies (now Thermo Fisher
Scientific, Waltham, MA), BP (London, UK), Dow Chemical
(Midland, MI), ExxonMobil (Irving, TX), and Goodyear Tire and
Rubber (Akron, OH), pharmaceutical companies like Glaxo-
SmithKline (London), Novartis (Basel, Switzerland), Merck
(White House Station, NJ), Pfizer (New York, NY), Roche (Basel),
and Sanofi-Aventis (Paris, France), and consumer products com-
panies such as LâOreÂŽal (Paris, France) and PepsiCo (Purchase,
NY)âare integrating synbio research into their R&D processes. A
number of start-ups are emerging from synbio-related research
activities and beginning to make their mark in the critically im-
portant areas of health, energy, environment, and food: e.g.,
Ginkgo BioWorks in Boston (engineered organisms), San Diego,
CA-based Genomatica (sustainable chemicals), and Amyris in
Emeryville, CA (energy and pharmaceuticals).
With research moving forward quickly and industry capitaliz-
ing on these developments, governmental regulatory bodies and
funding agencies are struggling to keep up. The patchwork of US
agencies and regulations can be confusing to practitioners and
regulators alike. Furthermore, while both the US and the EU have
established regulations to address synthetic biology, their ap-
proaches have not always aligned, and there is no agreement about
what exactly is being regulated and what constitutes the bound-
aries of ââsynthetic biology.ââ The global community has mobi-
lized around a few key initiatives, but the
US has remained conspicuously absent
from these discussions, choosing not to
sign on. It is imperative that the synbio
community continue its work with the US
government to refine its regulatory strat-
egy, both domestically and globally.
Considering the lack of clarity at the
governmental level, it is not surpris-
ing that public perception toward syn-
thetic biology is mixed. Most Americans
(roughly two-thirds) are in favor of syn-
bio research, a view shared by the UK
public.10,11
However, many are unfamil-
iar with exactly what synthetic biology
entails, and their concerns only increase
as they become more acquainted with the
concept.10
Questions about genetically
modified organisms (GMOs) and envi-
ronmental and biosafety risks are preva-
lent. Better communication and education
are required to support the growth of syn-
bio research and products, especially those
with a direct consumer connection (e.g.,
pharmaceuticals, food).
Synberc has spearheaded numerous
communication and educational initiatives
as well as fundamental advances in syn-
thetic biology. Synbercâs principal investigators have been critical
to creating a formative body of research, establishing synbio as an
important and viable effort oriented to the public good. Beyond
this, the organization has created innovative educational programs
to train future scientists and leaders. The Synberc community now
constitutes a national cadre of interdisciplinary researchers within a
focused, collegial community. It has also established the founda-
tion of a unique industrial-academic collaboration.
Synbio achievements to dateâfrom the International Geneti-
cally Engineered Machines (iGEM) competition, to BioBricks,
to registries like iGEMâs Registry of Standard Biological
Parts and the Joint BioEnergy Institute Inventory of Composable
Elementsâare inextricably linked to Synbercâs mandate and
activities. This highlights the pivotal role of the US in the overall
global success of synbio going forward and the imperative for a
strong central organizing force that will continue to support its
growth (both downstream and upstream markets), and mobilize
researchers, industry, government, and philanthropy.
Market Overview
Synthetic biology as an academic and research discipline is
not yet 15 years old, and as an industry, even younger. Core
technologies are in development, as foundational tools have yet
to mature; applications are still emerging as markets ponder how
best to profit from the vast potential; and synthetic biologyâs
products and applications have only begun to penetrate the many
markets it stands to disrupt. Regardless, a significant global
synthetic biology market, however immature, has established it-
self across multiple fields. The sheer number and diversity of
companies in the synbio space is telling. From 2009 to 2013, the
Fig. 1. Growth in synthetic biology research: Web of Science listings for ââSynthetic Biology.ââ
(Reprinted with permission from Oldham P, Hall S, Burton G. Synthetic biology: Mapping the
scientific landscape. PLoS One 2012;7:e34368)
SYNBIO MARKETS, NEEDS & APPLICATIONS
ÂȘ M A R Y A N N L I E B E R T , I N C . VOL. 10 NO. 3 JUNE 2014 INDUSTRIAL BIOTECHNOLOGY 141
3. Fig. 2. Synthetic biology highlights: representative timeline.2,6â8
KELLEY ET AL.
142 INDUSTRIAL BIOTECHNOLOGY JUNE 2014
4. estimated number of companies engaged in synbio worldwide
more than tripled, from 61 to 192 (Fig. 3).12
Two-thirds of these
companies are in the US, where the number of synbio commercial
entities grew from 54 to 131 in the same 2009â2013 period;
at least 43 European companies are engaged in synbio, and 13 in
Asia/Oceania. All regions are expected to see increases in the size
of synbio-enabled product markets through 2016, with North
America continuing to lead the industry.2
There is a dearth of directly relevant market research on syn-
thetic biology. NJKA surveyed available recent analyses and
found that few comprehensively describe the synbio landscape;
further, each seems to include market characterizations that differ
from each other and our observations.2,13,14
Despite understandable
challenges in sizing industrial biotechnology markets, there is a
clear need for more-incisive market studies.15
Nonetheless, some
trends are evident.
The global value of the synthetic biology market could grow
from $1.15 billion in 2010 to $10.84 billion in 2016.2,15
Rob Carlson
recently calculated the size of the US bioeconomyâthe ââGeneti-
cally Modified Domestic Product (GMDP)ââ and a superset of BCC
Researchâs synthetic biology marketâas $350 billion in 2012,
dwarfing these numbers by orders of magnitude. His data are drawn
from a number of sources and divide the bioeconomy into three
market sub-sectors: biotech drugs (biologics), genetically modified
crops, and industrial biotechnology (fuels, enzymes, and materials),
with particular attention paid to the value of end-user markets.15
)
This market can be divided into three segments, each pre-
dicted to demonstrate sizable growth through the next decade:
Enabling Technologies (basic technologies on which synbio
relies); Core Technologies (those that define synbio endeavors);
and Enabled Products (products, services, or platforms resulting
from or incorporating the end results of synbio processes, or that
include synbio components).2
These segments constitute a
simple value chain (Fig. 4).
ENABLING AND CORE TECHNOLOGIES
Enabling Technologies comprise tools and platforms necessary
for, but not specific to, synbio (e.g., DNA synthesis, sequencing,
specialty media, bioinformatics, data
management tools); their importance is in
their enablement of downstream produc-
tion. Marked reductions in cost for cer-
tain enabling technologies (specifically
synthesis and sequencing), together with
rapid increases in the amount of geno-
mic information, are vastly increasing
possibilities for industrial-scale synbio
systems, expanding the potential for
market growth in the other segments.2,16
Sequencing of the human genome, for
example, cost $2.7 billion and took 13
years in the first groundbreaking en-
deavor; some believe that within the
next decade sequencing a whole genome
will cost $100 and take 1 hour.16
Core
Technologies, including biological
components (integrated systems, en-
zymes, DNA parts, metabolic engi-
neering platforms), constitute a pivotal market segment.
Investment in this area will catalyze development of more end-
user products, and it is here that ongoing and future research
efforts will have the most impact.
ENABLED PRODUCTS
Enabled Products are the dominant synthetic biology seg-
ment, valued at $1.4 billion in 2011, and anticipated to grow to
as much as $4.5 billion by 2015, and $9.5 billion in 2016.2,17
Enabled Products can be further subdivided into several primary
markets, discussed below.
Chemicals. Chemicals dominate the synbio industry; some
estimates suggest up to 20% of the current $1.8 trillion chemical
industry could eventually be dependent on synbio.18
Many
available synbio chemicals are important products in the tradi-
tional petroleum-refinery value chain: succinic acid (BioAmber,
Montreal, Canada; DSM, Heerlen, The Netherlands), 1,3-
propanediol (Tate Lyle, London; Genencor/DuPont, Palo
Alto, CA), isobutanol (Gevo, Engelwood, CO), d(-)lactic acid
(Myriant, Quincy, MA), and 1,4-butanediol (BDO; Genomatica/
Tate Lyle).19
In addition, enzymes have long constituted an
important industrial market in their own right, with numerous
uses in consumer products and industrial production processes
(in textiles, pulp and paper treatments, detergents, etc.). Preci-
sion-designed enzymes will become increasingly important,
Fig. 3. Entities conducting research in synthetic biology worldwide.12
Fig. 4. Synthetic biology product value chain.
SYNBIO MARKETS, NEEDS APPLICATIONS
ÂȘ M A R Y A N N L I E B E R T , I N C . VOL. 10 NO. 3 JUNE 2014 INDUSTRIAL BIOTECHNOLOGY 143
5. particularly for biofuels. Overall, end-use applications are
varied and pervasive (Figure 5).
Energy. Much of the history of applied synthetic biology is
commingled with biofuels, with the result that disappointing
shortfalls in anticipated targets for commercial-scale biofuels
production have been setbacks for both.20
Nonetheless, persis-
tent US government interest in advancing next-generation (non-
corn lignocellulosic, algae, and other) biofuels and biopower is
supporting continued efforts by companies like Amyris, Sola-
zyme (South San Francisco, CA), Qteros (Marlborough, MA),
Genencor/DuPont, and Algenol (Fort Myers, FL), to develop
biobased production platforms, feedstocks, and products.21
As
many as 530 biorefineries, each with mean capacity of 40 million
gallons annually, could be required to meet the goals of the US
Environmental Protection Agencyâs 2007 amended Renewable
Fuel Standard (RFS2), which stipulated 36 billion gallons of re-
newable fuel blended into national transportation fuel supplies by
2036.22,23
Agriculture. Engineering of complex traits in higher plants has
yet to move beyond research endeavors. The need for mass-
volumes of biofeedstocks with high energy yields, lower input
requirements, and greater environmental hardiness, for large-
scale production of chemicals and fuels, should drive continued
efforts for agricultural synbio. One possible nearer-term use may
stem from Synberc investigations to exploit the nitrogen-fixation
capacity of Klebsiella oxytoca, with downstream potential for
management of soil nitrogen from chemical fertilizers.24
Other markets. Synthetic biology stands to be massively dis-
ruptive in several other markets. Current diagnostics and phar-
maceutical applications center on improving existing methods
to produce on-market drugs (e.g., Codexisâ [Redwood City, CA]
directed evolution for optimized
production for Merck, Pfizer,
Teva, Roche, DSM) and to facili-
tate vaccine production (Amyris
and Sanofi-Aventisâ antimalarial
precursor production; Novartisâ
rapid-response H7N9 influenza
vaccine).25â27
Future advances
will include synthetic self-ampli-
fying mRNA vaccines, cell-based
therapeutics, and as yet elusive
personalized medicines (including
effective cancer treatments).26,27
Designed microorganisms for
environmental remediation have
been demonstrated by Modular
Genetics (partnering with Iowa
State University), which devel-
oped microorganisms that produce
soy-based biodispersants for oil-
pollution management (e.g., the
2010 Deepwater Horizon oil spill,
supported by an NSF Rapid Re-
sponse Grant of $200,000).28
The myriad sensing and response
pathways of cells are being harnessed for development of bio-
sensors, for applications from food safety to bioterror-agent
detection. The synbio-enabled capacity to detect arsenic in
drinking water was demonstrated by an iGEM team as early as
2006; a sophisticated evolution of this concept is in implantable,
bioresorbable biosensors for frontline military, a project cur-
rently supported by DARPA.29,30
While the field still awaits a
steady stream of successes, the market for synbio products is
nonetheless evolving and growing rapidly, as indicated by the
number of technologies moving synbio companies to maturity,
successful public offerings, and strategic ventures with estab-
lished industry leaders and government agencies.
TECHNOLOGY READINESS
The growth of these applications critically depends on avail-
ability of foundational and translational technology. The US
government has noted that synbio still requires ââsubstantial basic
and applied RD to realize its full potential as an engineering
and scientific discipline and as a viable tool set for commercial
biotechnology.ââ31
A recent international survey of approxima-
tely 150 self-identified synthetic biology researchers revealed a
breadth of options available to synbio researchers, including
various public registries, assembly standards, and software
toolsâmany, well established and in the public domain and
others available through non-exclusive licensing (Figure 6).32
Still, several areas of need remain, calling for continued re-
search investment. The DOE has identified critical fundamental
knowledge gaps in methods and technologies (genome-scale
engineering tools, DNA synthesis and assembly, analytical
tools), biological platforms (biological design principles, ge-
netically tractable organisms/chassis, minimal cell and in vitro
systems, tools for plant systems, biocontainment), and compu-
tational tools and bioinformatics (information standards, data-
bases).31
Continued efforts must build on the foundational
Fig. 5. Breakdown of specialty/fine chemical applications worldwide.12
KELLEY ET AL.
144 INDUSTRIAL BIOTECHNOLOGY JUNE 2014
6. sciences established to date while addressing these key research
needsâa concept that governments worldwide are acknowl-
edging.
Public Research Landscape
UNITED STATES
Challenges must be overcome before the needed research de-
velopments described can occur. In the US (and elsewhere), synbio
research lacks a single, coordinated governmental funding plan.
US funding is spread among agencies, and industry analysts note
that concrete numbers on US funding are difficult to come by due
to missing information, an uncoordinated government approach,
and varied definitions for synthetic biology. Still, the US govern-
ment has spent more money to support synthetic biology than has
Europe or Asia: at least $500 million by 2010 and as much as $140
million per year1
since the fieldâs inception, by some estimates.3,6,9
Important US agencies that impact the field include the NSF,
DOE, Department of Health and Human Services (including
NIH), DOD (including DARPA), Department of Agriculture
(USDA), US Navy, Air Force, and National Aeronautics
and Space Administration (NASA). The White House Office of
Science and Technology Policy (OSTP) is increasingly looking to
coordinate synthetic biology efforts across agencies. OSTPâs
Technology and Innovation Division has voiced a keen interest in
synbio and adjacent disciplines (systems biology, bioprocessing,
and biomanufacturing) and has engaged with DARPA and other
agencies to identify collaboration opportunities. Still, a coordi-
nated national effort on the scale of the National Nanotechnology
Initiative seems unlikely.
Regardless, while the US may lack a solidly coordinated, in-
tegrated research strategy, there is some level of support for syn-
thetic biology across many agencies that appears to be growing. A
more coordinated and defined research effort, properly commu-
nicated and managed by the synbio research community, would
likely translate into greater and more-coordinated government
funding. Conversations with government representatives consis-
tently identified the lack of a collective US vision for synbio,
driven by research and commercial interests, to guide independent
but aligned investments from US agenciesâinvestments required
to grow the base of foundational technologies that will allow syn-
thetic biology to fulfill its greatest promise. (Also missing for the
OSTP may be a more appropriate term than ââsynthetic biology,ââ
which may do more harm than good in Washington, DC. Both
OSTP and DARPA prefer ââengineering biology,ââ which is per-
ceived as more inclusive and less polarizing. Others in the com-
munity disagree that the name should be changed.)
EUROPEAN UNION
European biosciences research is funded through a complex,
tiered web of organizations and time-limited initiatives, at
modest levels compared to the US (on the order of tens of
millions of dollars, versus the 100-million-dollar scale of some
US initiatives, like DARPAâs Living Foundries Programs;
www.darpa.mil/our_work/). We found no central data reposi-
tory that clearly explains the different European programs and
the relationships among them, which may indicate the level of
bureaucracy of both research and regulatory initiatives in the
EU that include both overarching EU and individual Member
State activities.
The take-away is that while
synbio is becoming a cohesively
orchestrated EU initiative it is still
very much in early development. A
European Commission EU-funded
project, ââTowards a European
Strategy in Synthetic Biology
(TESSY),ââ was used to outline a
roadmap for European synthetic
biology around scientific mile-
stones, knowledge transfer, fund-
ing, and regulation. ERASynBio
represents a major first initiative
through which national Member
State funding bodies aim to sup-
port common goals. ERASynBio
is integrating emerging national
activities into a coordinated Euro-
pean effort. Specific objectives
include development of research
programs, strategies, and infra-
structures that preempt fragmen-
tation of programs, regulatory
frameworks, and policies; initiation
and implementation of transna-
tional research funding; and co-
herence of a fragmented European
research landscape. In April 2014,Fig. 6. Enabling technologies in synthetic biology.33
SYNBIO MARKETS, NEEDS APPLICATIONS
ÂȘ M A R Y A N N L I E B E R T , I N C . VOL. 10 NO. 3 JUNE 2014 INDUSTRIAL BIOTECHNOLOGY 145
7. ERASynBio published a report, ââNext Steps for European Syn-
thetic Biology: A Strategic Vision from ERASynBio,ââ which
outlines its recommendations across five broad themes that en-
compass world-leading research, responsible innovation, global
community, skilled workforce, and open data.
UNITED KINGDOM
The UK is second only to the US in synthetic biology research
(by publication activity) and leads Europe in the number of synbio
companies and dedicated institutes.3,34
The country completed a
synbio roadmap in 2012, and synthetic biology became an area of
formal focus for the UK government when it was formally declared
one of ââeight great technologiesââ that will impel the countryâs
economic growth (the eight being life sciences, genomics and
synthetic biology; big-data revolution and energy-efficient com-
puting; satellites and commercial applications of space; robotics
and autonomous systems; regenerative medicine; agri-science;
advanced materials and nanotechnology; and energy and its stor-
age).35
To date, maximum funding initiatives have typically been in
the range of tens of millions of dollars; however, a government
commitment of over $133.5 million in the coming years was an-
nounced in early 2013 by the countryâs Ministry of State for Uni-
versities and Science.36
The two main synbio funding councils,
The Biotechnology and Biosciences Research Council (BBSRC)
and The Engineering and Physical Sciences Research Council
(EPSRC), have demonstrated clear commitment to advancing
both fundamental and translational research. More recently, in
April 2014, the BBSRC announced investments of nearly $17
million to establish five DNA synthesis centers across the UK and
$3.4 million to enhance student training in synthetic biology.
CHINA
While Chinaâs economic policies have been nationalistic, the
countryâs acknowledgment of critical needs for its population may
be encouraging a more cooperative approach that could open
opportunities for synbio within the country and with other nations.
(Chinaâs 12th
Five-Year Program, announced in 2010, formally
recognizes the need for openness and international collaboration.6
)
Chinaâs burgeoning citizenry of 1.3 billion represents one-fifth of
the global population. Given urgent needs in health, nutrition, and
resources management, the Chinese government is motivated to
have synbio research advance to real-world applications. The
country has drafted a strategic roadmap outlining opportunities
over the next 5, 10, and 20 years, with goals for comprehensive
databases of synthetic parts, and time frames both for commercial
application of engineered parts and clinical application of devices
and systems.6
The Chinese Academy of Sciences (CAS) intends
that synbio research in China be ââamong the best in the world in
5â10 years,ââ a likelihood given Chinaâs clear commitment to
RD overall; the country intends to increase its RD spending
from 1.5% of its GDP to 2.5% in 2020.5,37
Funding for Chinese synbio research comes from many
sources, including the National Natural Science Foundation of
China, state-level laboratories, and the CAS Knowledge In-
novation Program. Research expenditures by the country total
approximately $100 billion, though only $32.5 million is allo-
cated specifically for synthetic biology.6
Unlike in the US, much
of the research financing is state-controlled; Chinaâs central
party holds powerful sway over research directions, with large
budgets at its disposal allocated according to 5-year RD pri-
orities focused in areas ââof national urgency.ââ6
Regulatory Landscape
The regulatory landscape governing synbio is complex. In-
ternational agreements are difficult to reach and sometimes
criticized for not being comprehensive. Governments differ in
domestic approaches, which may render compliance processes
difficult and expensive to manage. Meanwhile, it is synbio
scientists who have been at the forefront in developing and re-
commending solutions to problems and potential challenges that
arise as the field evolves.
Regulatory approaches have both top-down and bottom-up
aspects. Top-down regulations set standards for proper labora-
tory use and environmental safety standards, establish weapons
non-proliferation practices, and further humanitarian research.
Bottom-up approaches involve engineering biological safe-
guards into organisms, screening and tracking orders for DNA
sequences, and developing safe and ethical laboratory practices.
The International Risk Governance Council (IRGC) has clas-
sified concerns of civic watchdog groups, industry experts, law-
yers, ethicists, and governmental organizations into seven themes:
. Insufficient basic knowledge about potential risks posed by
designed and synthetic organisms
. Uncontrolled release (accidental or deliberate) of novel
genetically modified organisms with environmental or
human health implications
. Bioterrorism, biological warfare, and construction of
novel, hostile organisms
. Emergence of a ââbio-hackerââ culture, with unregulated
individuals developing dangerous organisms
. Patenting of genetic material and creation of monopolies
controlling these resources
. Trade and global justice (exploitation of indigenous re-
sources, or distortion of land-use agendas for large-scale
biomass feedstocks)
. Creation of artificial life and related philosophical and
religious concerns38â41
The challenge is that, similar to the research-funding landscape,
regulatory oversight is unclear and disorganized across inter-
national, national, and regional levels. Several international
approaches to biological weapons have emerged, such as ââThe
Convention on the Prohibition of the Development, Production
and Stockpiling of Bacteriological (Biological) and Toxin
Weapons and on their Destructionââ (commonly known as the
Biological Weapons Convention), which formed ââthe first
multilateral disarmament treaty banning the development, pro-
duction and stockpiling of an entire category of weapons of mass
destruction.ââ42
Critics, however, are quick to note that inter-
national agreementsâ ââslow consensual nature is not well suited
to addressing unconventional risks posed by non-state actors.ââ43
Additional international agreements have been negotiated,
including the ââConvention on Biological Diversity (CBD)
Cartagena Protocol on Biosafetyââ and subsequent ââNagoya
KELLEY ET AL.
146 INDUSTRIAL BIOTECHNOLOGY JUNE 2014
8. Protocol,ââ and the World Health Organizationâs ââBiosafety
Standards Manual.ââ44
The US has signed but not ratified the
CBD and is therefore precluded from ratifying the ââNagoya
Protocolâââpreventing the country from assuming its critical
leadership in these important conversations.
Domestically, US synbio activity is subject to an overlapping
but uncomprehensive patchwork of regulations across multiple
agencies. As Synberc and iGEM leadership have concluded,
existing regulations may not be either enforced or enforceable.
This lack in oversight will be increasingly important as synbio
progresses and the more-inventive possibilities materialize (of
heretofore nonexistent genetic functions), especially in the
hands of citizen researchers in the Do-It-Yourself (Synthetic)
Biology (DIYbio) movement.
DIYbio has emerged over the past decade and presents both
challenges and opportunities for regulatory oversight and public
perception. It puts bioengineering tools in the hands of citizen
scientists, under the premise ââthat wider access to the tools of
biotechnology, particularly.related to the reading and writing of
DNA, has the potential to spur global innovation and promote
biology education and literacy.ââ45
This community was inspired
by Rob Carlsonâs home biology lab, gained a voice with DIY-
bio.org (a message board launched in 2005), and has since ex-
panded to at least 14 labs in North America and Europe.46
Among
the more prominent are Genspace (Brooklyn, NY) and BioCurious
(Sunnyvale, CA). The latter made a name for itself as an innovator
by crowdfunding its start-up costs, successfully building a ââbio-
printerââ (a 3D printer that prints using biological materials), and
housing a community project that created the controversial,
groundbreaking Glowing Plant (glowingplant.com), seeds for
which are now offered for sale through Glowing Plantâs website.
The DIYbio movement has obvious potential to stir concerns
about public safety. However, there is a great opportunity
for grassroots community efforts like these both to spur inno-
vation and foster the public education needed for synbio to
mature. Still, in order to succeed, new financial models for
community labs must emerge, additional community resources
will likely be required, and sufficient regulatory oversight must
be established. With these in place, the potential for DIYbio to
be a positive contributor to the fieldâand the greater goodâis
significant.
An additional regulatory concern is that NIH guidelines (the
most comprehensive available to date) are not binding on all
individuals conducting synbio research.47
As one report states:
Products are currently covered by three different US agencies
operating under four separate statutes. The result is a regulatory
system marked by fragmentation, lack of coordination, and dif-
ferent standards for different types of products.Differences in
statutory mandates, risk assessment methodologies, and agency
cultures.create a system where the stringency of the risk as-
sessment and approval process is more dependent on the specific
product category than on the risk of the product.47
There is a clear opportunity for the US to take a more focused,
integrated, and global approach to synbio regulationâwith
support from the research communityâin advocacy, education,
and collaboration. Without this, ambiguous regulatory policies
(as well as lack of capacity) may constrain the full potential of
synbio in the US and the world going forward.
Public Awareness
The ultimate success of synbio will depend on acceptance by
public stakeholders, both as citizens and consumers. Within the
US, public opinion on synthetic biology is cautious but open:
nearly two-thirds of Americans surveyed believe synthetic bi-
ology research should continue rather than be banned, even if its
implications and risks are not fully understood.10
Similar opin-
ions exist in the UK (although public opinion there varies by the
nature of the end product, means to achieving that product, and
by gender, region, and age).48
It is important to note that most Americans are unsure about
what synthetic biology is. As the ultimate stakeholders in any
governmental regulatory decisions, consumers must be equip-
ped with factual information about the vast potential benefits of
synthetic biology, as well as its risks, and the measures being
undertaken to address these. Public education and engagement
are essential to the future growth of this field.
Conclusions
The US has been a leader in the development and commer-
cialization of synthetic biology. It has produced more high-
impact foundational and translational research than any other
nation, and its technology infrastructure is in many ways a
model of industry, government, and academic cooperation. But
the United Statesâ continued leadership in synthetic biology is
not guaranteed. Other countries, including the super economy
of China, and some within the collective entity of the Euro-
pean Union, are investing heavily to assure their own strength
in applying synthetic biology to address the needs of their
citizenries.
The US must therefore renew and grow its commitment to
synthetic biology, in investment, policy, and public education,
or risk falling behind in an industry and research sector that it has
pioneered. To realize the true promise of this emerging field,
much more foundational research is needed, as are continued
funding and rationalized regulations (both domestic and inter-
national) that facilitate the safe deployment of these technolo-
gies for the greatest good, with the public truly engaged. The
time is now to bring public and private actors together to create a
strategic direction for synthetic biology consistent with US na-
tional priorities and values.
Nancy J. Kelley, JD, MPP, was the Founding Executive Director of the New York
Genome Center. David J. Whelan, MBA, served as Senior Vice President, Business
Development and Chief Strategy Officer for the New York Genome Center.
Additional members of the NJKA team also contributed to this report.
Contact: Nancy J. Kelley, Nancy J. Kelley Associates, New York, NY. Email:
nancy@nancyjkelley.com
R E F E R E N C E S
1. Synthetic biology community. Available at www.synthetic biology.org (Last
accessed December 2013).
SYNBIO MARKETS, NEEDS APPLICATIONS
ÂȘ M A R Y A N N L I E B E R T , I N C . VOL. 10 NO. 3 JUNE 2014 INDUSTRIAL BIOTECHNOLOGY 147
9. 2. BCC Research. Synthetic Biology: Emerging Global Markets. Wellesley, MA,
2011.
3. Oldham P, Hall S, Burton G. Synthetic biology: Mapping the scientific landscape.
PLoS One. 2012;7:e34368.
4. Nancy J. Kelley Associates. Synberc Sustainability Initiative: Initial Findings
Recommendations. New York, NY, February 4, 2014, Available at http://bit.ly/
NJKAsynbio (Last accessed April 2014).
5. Chinese Academy of Sciences. Science Technology in China: A Roadmap
to 2050: Strategic General Report of the Chinese Academy of Sciences.
2009; cited in Joyce S, Mazza AM, Kendall S. Positioning Synthetic Biology to
Meet the Challenges of the 21st Century: Summary Report of a Six
Academies Symposium Series. Washington, DC: The National Academies
Press, 2013.
6. Joyce S, Mazza AM, Kendall S. Positioning Synthetic Biology to Meet the
Challenges of the 21st Century: Summary Report of a Six Academies
Symposium Series. Washington, DC: The National Academies Press, 2013.
7. LabGenius. Synthetic biology timeline. Available at www.labgeni.us/
synbiotimeline/ (Last accessed April 2014).
8. Purnick PEM, Weiss R. The second wave of synthetic biology: From modules to
systems. Nat Rev Mol Cell Biol 2009;10:410â422.
9. Synthetic Biology Project. Trends in Synthetic Biology Research Funding in
the United States and Europe: Research Brief 1. Washington, DC: Woodrow
Wilson International Center for Scholars, June 2010. Available at
www.synbioproject.org/library/publications/archive/researchfunding/ (Last
accessed April 2014).
10. Hart Research Associates (for Woodrow Wilson International Center for
Scholars). Awareness Impressions of Synthetic Biology: A Report of Findings
Based on a National Survey among Adults. Washington, DC, March 2013.
Available at www.synbioproject.org/process/assets/files/6655/
synbiosurvey2013.pdf (Last accessed April 2014).
11. The Royal Academy of Engineering. Synthetic Biology: Public Dialogue On
Synthetic Biology. London, UK, 2009.
12. Synthetic Biology Project. Tracking the Growth of Synthetic Biology: Findings
for 2013. Washington, DC: Woodrow Wilson International Center for Scholars,
2013. Available at www.synbioproject.org/library/publications/archive/
researchfunding/ (Last accessed April 2014).
13. Bušnger M. BioPunks and BioPatents: The Open-Source Battle Comes to Synbio
IP. Boston, MA: Lux Research, 2013.
14. Transparency Market Research. Synthetic Biology Market: Global Industry
Size, Market Share, Trends, Analysis and Forecast, 2012â2018. Albany, NY,
2012. Available at www.transparencymarketresearch.com/ (Last accessed April
2014).
15. Carlson R. The U.S. Bioeconomy in 2012 reached $350 billion in revenues, or
about 2.5% of GDP. (2014) Available at www.synthesis.cc/2014/01/the-us-
bioeconomy-in-2012.html (Last accessed April 2104)
16. Manyika J, Chui M, Bughin J, et al. Disruptive technologies: Advances that will
transform life, business, and the global economy. San Francisco, CA:
McKinsey Global Institute, May 2013. Available at www.mckinsey.com/
insights/business_technology/disruptive_technologies (Last accessed April
2014).
17. Global Industry Analysts, Inc. Synthetic BiologyâA Global Strategic Business
Report. November 2013. Available at www.marketresearch.com/Global-
Industry-Analysts-v1039/Synthetic-Biology-7961719/ (Last accessed April
2014).
18. Synthetic Biology Project. Trends in Synthetic Biology Research Funding in
the United States Europe. Washington, DC: Woodrow Wilson International
Center for Scholars, June 2010. Available at www.synbioproject.org/library/
publications/archive/researchfunding/ (Last accessed April 2014).
19. Synthetic Biology Project. Inventory of Synthetic Biology Products, Existing
Possible (draft). Washington, DC: Woodrow Wilson International Center for
Scholars, 2012.
20. US Department of Energy, Office of Inspector General, Office of Audits and
Inspections. Audit Report: Follow-up Audit of the Department of Energyâs
Financial Assistance for Integrated Biorefinery Projects. DOE/IG-0893.
Washington, DC, September 2013.
21. Office of Science and Technology Policy, Executive Office of the President.
National Bioeconomy Blueprint. Washington, DC, April 2012. Available at
www.whitehouse.gov/sites/default/files/microsites/ostp/national_bioeconomy_
blueprint_april_2012.pdf (Last accessed April 2014).
22. US Department of Agriculture. USDA Biofuels Strategic Production Report:
A USDA Regional Roadmap to Meeting the Biofuels Goals of the Renewable
Fuels Standard by 2022. Washington, DC, June 2010. Available at
www.usda.gov/documents/USDA_Biofuels_Report_6232010.pdf
(Last accessed April 2014).
23. US Environmental Protection Agency. Renewable Fuels Standard (RFS).
Washington, DC, Available at www.epa.gov/otaq/fuels/renewablefuels/
index.htm (Last accessed December 2013).
24. Synberc. Synberc Year Seven Report. Emeryville, CA, February 20, 2012.
25. Codexis Corporate Fact Sheet. Available at www.codexis.com/documents/
Codexis_FactSheet2013.pdf (Last accessed December 2013).
26. Jain K. Synthetic biology and personalized medicine. Med Princ Pract
2013;22;209â219.
27. Dormitzer PR. Synthetic Vaccinology at Novartis. National Academy of Sciences
Forum on Synthetic Biology. Washington, DC, October 21, 2013.
28. Modular Genetics, press release. Modular Genetics and Iowa State University
Developing Microorganisms to Clean up the Massive BP Oil Spill. June 11,
2010. Available at www.enhancedonlinenews.com/portal/site/eon/permalink/
?ndmViewId = news_viewnewsId = 20100611006238 newsLang = en (Last
accessed April 2014).
29. iGEM: University of Edinburgh 2006. Available at http://2006.igem.org/
University_of_Edinburgh_2006. (Last accessed April 2014).
30. DARPA. DARPA Small Business Innovation Research (SBIR) Proposal Submission
Instructions. www.acq.osd.mil/osbp/sbir/solicitations/sbir20131/darpa131.htm
(Last accessed December 2013).
31. US Department of Energy. Synthetic Biology: Report to Congress. July 2013.
32. Kahl LJ, Endy D. Survey of enabling technologies in synthetic biology. J Biol Eng
2013;7:13.
33. Kahl LJ. Enabling technologies of synthetic biology: Ownership, access
sharing. Presented at BioBricks SB6.0, July 9â11, 2013, London, UK.
34. Synthetic Biology Project. Tracking Synthetic Biology in Europe. Washington,
DC: Woodrow Wilson International Center for Scholars, 2013. Available at
www.synbioproject.org/library/publications/archive/researchfunding/ (Last
accessed April 2014).
35. Rt. Hon. David Willetts MP. Eight Great Technologies. Available at
www.gov.uk/government/speeches/eight-great-technologies (Last accessed
December 2013).
36. UK Government. ÂŁ600 Million Funding Boost for Science and Research.
Available at www.gov.uk/government/news/600-million-funding-boost-for-
science-and-research (Last accessed December 2013).
37. China calling. Nat. Biotechnol (editorial). 2011;29(2):89.
38. International Risk Governance Council. Guidelines for the Appropriate Risk
Governance of Synthetic Biology. 2010. Available at www.irgc.org/IMG/pdf/
irgc_SB_final_07jan_web.pdf (Last accessed April 2014).
39. European Commission. Ethics of Synthetic Biology, Opinion of the European
Group on Ethics in Science and New Technologies to the European Commission.
May 19, 2009. Available at http://ec.europa.eu/bepa/european-group-ethics/
docs/publications/round_table_ethical_aspects_of_synthetic_biology_en.pdf
(Last accessed April 2014).
40. Friends of the Earth. Synthetic Solutions to the Climate Crisis: The Dangers of
Synthetic Biology for Biofuels Production. September 2010. Available at http://
KELLEY ET AL.
148 INDUSTRIAL BIOTECHNOLOGY JUNE 2014
10. libcloud.s3.amazonaws.com/93/59/9/529/1/SynBio-Biofuels_Report_Web.pdf
(Last accessed April 2014).
41. Gibson DG, Glass JI, Lartigue C, et al. Creation of a bacterial cell controlled by a
chemically synthesized genome. Science 2010;329:52â56.
42. United Nations Office for Disarmament Affairs. Biological Weapons Convention.
Available at www.un.org/disarmament/WMD/Bio/ (Last accessed April 2014).
43. Organisation for Economic Co-operation and Development. The Bioeconomy to
2030: Designing a Policy Agenda. 2010. Available at www.oecd.org/futures/
long-termtechnologicalsocietalchallenges/thebioeconomyto2030designing
apolicyagenda.htm (Last accessed April 2014).
44. World Health Organization. Laboratory Biosafety Manual, 3rd ed. Geneva,
Switzerland, 2004.
45. Synthetic Biology Project Seven Myths and Realities about Do-It-Yourself
Biology. Washington, DC: Woodrow Wilson International Center for Scholars,
2013. Available at www.synbioproject.org/process/assets/files/6673/_draft/7_
myths_final.pdf (Last accessed April 2014).
46. Carlson R. Splice It Yourself. Wired. May 2005.
47. Bar-Yam S, Byers-Corbin J, Casagrande R, et al. The Regulation of Synthetic
Biology: A Guide to United States and European Union Regulations, Rules
Guidelines. January 2012. Available at http://synberc.org/sites/default/files/
Concise%20Guide%20to%20Synbio%20Regulation%20OYE%20Jan%202012_0
.pdf (Last accessed April 2014).
48. The Royal Academy of Engineering. Synthetic Biology: Public Dialogue on
Synthetic Biology. London, UK, 2009.
SYNBIO MARKETS, NEEDS APPLICATIONS
ÂȘ M A R Y A N N L I E B E R T , I N C . VOL. 10 NO. 3 JUNE 2014 INDUSTRIAL BIOTECHNOLOGY 149